Infinity to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

On November 22, 2021 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, reported that Adelene Perkins, Chief Executive Officer, will present at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference (Press release, Infinity Pharmaceuticals, NOV 22, 2021, View Source [SID1234595891]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be a fireside chat with Ted Tenthoff, Piper’s Senior Biotech Analyst, which will be available on the Company’s website beginning November 22nd. Management will also be available for 1-on-1 meetings with investors during the conference which will take place November 29th through December 2nd.

Presentation details can be found below:

33rd Annual Virtual Healthcare Conference
Format: Presentation and 1-on-1 meetings
Date and Time: Presentation available starting Monday, November 22nd at 10:00am ET; 1-on-1 meetings November 29th – December 2nd
The presentations and archived webcasts can be accessed in the Investors/Media section of Infinity’s website at www.infi.com and will be available on Infinity’s website for 30 days following the event.

MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-Oncology

On November 22, 2021 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), reported that MediciNova’s research collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, presented new data regarding MN-166 (ibudilast) from a glioblastoma animal model study at the 26th Annual Meeting of the Society for Neuro-Oncology (SNO) held November 18 – 21, 2021 in Boston (Press release, MediciNova, NOV 22, 2021, View Source [SID1234595910]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This study was a collaborative effort between MediciNova and Dr. Lathia and Dr. Michael Vogelbaum, Professor of Neurosurgery, Chief of Neurosurgery and Program Leader of the Department of Neuro-Oncology at Moffitt Cancer Center.

Dr. Lathia presented efficacy data with MN-166 and PD-1 inhibitor combination therapy in GBM pre-clinical models. Models with GBM orthotopic tumors were treated with a PD-1 antibody alone and in combination with MN-166. Treatment was initiated at day 7 post-engraftment with 3 intraperitoneal injections 3 days apart. Treatment with a PD-1 inhibitor alone extended median survival from 17 to 28 days in this model, compared to control vehicle or non-specific antibody treatments. The addition of MN-166 to PD-1 inhibitor treatment significantly extended survival to a median of 66 days (p<0.001). This experiment was based on the hypothesis that inhibition of macrophage migration inhibitory factor (MIF) signaling via MIF-CD74 inhibition sensitizes GBM to treatment with an immune checkpoint inhibitor.

Dr. Lathia commented "Previously we identified MN-166, as a brain-penetrant MIF-CD74 interaction inhibitor which reduced myeloid-derived suppressor cells (MDSC) generation and reversed their T cell suppressive capacity in-vitro. In MN-166 treated models, we observed reduced monocytic-MDSCs and an increase of CD8+ T cell number and function in the tumor microenvironment. We are pleased to present this new data in which MN-166 and PD-1 inhibitor combination treatment significantly extended survival in a GBM orthotopic animal model. This new data is encouraging to support our hypothesis that targeting MDSCs with a MIF-CD74 blocker sensitizes GBM to anti-PD-1 therapy and improves survival."

Kazuko Matsuda, M.D. Ph.D, MPH., Chief Medical Officer, MediciNova, Inc., commented, "GBM is the most common primary malignant brain tumor with a very poor prognosis. GBM is a highly immunosuppressive tumor and there are limitations in terms of a safe immune response in the central nervous system. The advent of immune checkpoint inhibitors improved survival and prognosis of many people suffering with solid tumors, such as malignant melanoma, non-small cell lung cancer, and renal cell carcinoma. However, to date, targeted therapies comprising single components have only shown limited efficacy in clinical trials of GBM. Drug resistance is one of the main reason for the failure of immune checkpoint blockade therapy. We are very excited with this new MN-166 data that MN-166 sensitized GBM to immune checkpoint inhibitor treatment. We are looking forward to moving to a clinical trial of MN-166 in combination with an immune checkpoint inhibitor."

About MN-166 (ibudilast)

MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases including ALS, progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); glioblastoma, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) is being evaluated in patients at risk for developing acute respiratory distress syndrome (ARDS).

Inspirna to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

On November 22, 2021 Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, reported that CEO Masoud Tavazoie, M.D., Ph.D., will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 A.M. EST on November 22, 2021 (Press release, Inspirna, NOV 22, 2021, View Source [SID1234595927]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A pre-recorded webcast of the presentation will be available at the time of the presentation and will be available on Inspirna’s website within the News section.

Twist Bioscience Enters into Definitive Agreement to Acquire Abveris, Bolstering Biopharma Capabilities

On November 22, 2021 Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, reported it entered into a definitive agreement to acquire Abveris, (formally known as AbX Biologics, Inc.) a privately held in vivo antibody discovery services company developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global biopharma leaders (Press release, Twist Bioscience, NOV 22, 2021, View Source [SID1234595947]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abveris offers comprehensive antibody discovery and characterization services using its proprietary DiversimAb family of hyperimmune mouse models, the output of which can be humanized using the Twist antibody optimization solution to develop superior biologics for rapid clinical advancement.

"The addition of the Abveris discovery platform is a natural fit with Twist as it will complement and extend our biopharma antibody capabilities into mouse-based discovery and screening," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "There are three key approaches to antibody discovery: synthetic libraries, which is the specialty of Twist; in vivo discovery through animal models; and artificial intelligence models. With the anticipated acquisition of Abveris, Twist will have expertise in each, creating a robust antibody design, discovery and screening organization to serve both our partners and our internal pipeline."

"We look forward to integrating our proprietary in vivo discovery platform with the Twist lead optimization workflow to consolidate and streamline the process of identifying the highest quality development ready drug candidates for our partners," said Tracey Mullen, CEO of Abveris. "By combining the two highly synergistic approaches, Twist will be able to pair natural, in vivo antibody development with its industry-leading humanization and engineering capabilities to introduce a new gold standard in antibody discovery. We are thrilled to play an integral role in this revolution."

The total purchase consideration of up to $190 million includes $150 million in consideration to be issued at the closing of the transaction, consisting of shares of Twist common stock and up to $10 million in cash, subject to customary adjustments for cash, net working capital, outstanding indebtedness and unpaid transaction expenses, and up to $40 million shares of Twist common stock, to be issued contingent on and subject to Abveris achieving an internal revenue target for the calendar year 2022. The applicable price per share of Twist common stock is the average per share closing sale price of Twist common stock for the 30 consecutive trading day period prior to and including the date that is two trading days immediately preceding the closing, and which will not fall below $106.10 or exceed $129.68.

Edgemont Partners acted as exclusive financial advisor to Abveris, and Nutter, McClennen & Fish LLP acted as legal advisor to Abveris.

Conference Call Information

The company plans to hold a conference call and live audio webcast for analysts and investors today at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company’s business, including the acquisition of Abveris. The call can be accessed by dialing (866) 688-0947 (domestic) or (409) 217-8781 (international) and refer to the conference ID 4608297. A telephonic replay of the conference call will be available beginning approximately four hours after the call through November 29, 2021 and may be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international). The replay conference ID is 4608297. The webcast replay will be available for two weeks. If a participant will be listen-only, they are encouraged to listen via the webcast on Twist’s investor page.

CLTX CAR T Final SNO Presentation Provides Additional Clinical Insight
Showing Regional Control of Tumour Recurrence

On November 22, 2021 Chimeric Therapeutics (ASX:CHM, "Chimeric"), a clinical-stage cell therapy company and the ASX leader in cell therapy, reported to highlight key additional data released with the final presentation of two CLTX CAR T abstracts at the Society for Neuro-Oncology (SNO) 26th annual scientific meeting (Press release, Chimeric Therapeutics, NOV 22, 2021, View Source [SID1234595874]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract CTIM-29, "Clinical evaluation of chlorotoxin-directed CAR T cells for patients with recurrent glioblastoma" provides insight into the initial clinical data for CLTX while abstract EXTH-10, "Exploration of a novel toxin-incorporating CAR T cell: how does chlorotoxin recognize glioblastoma cells?" expands on the translational understanding of Chlorotoxin (CLTX) activity.

The clinical data presented in abstract CTIM-29 is from the ongoing CLTX CAR T phase 1 clinical trial in patients with MMP2+ recurrent or progressive glioblastoma. The data focuses on the four patients enrolled in dose level 1 of the trial, treated with 44 X 106 CLTX CAR T cells through a single route of intratumoral administration. Dose escalation in this trial is planned across four dose levels to a total dose of 440 X 106 CLTX CAR T cells administered through dual intratumoral and intraventricular routes of administration

Of significant note, during the final presentation MRI scans presented of patient 487 demonstrated no recurrence of tumour in the left frontal lobe where CLTX CAR T cells were infused, two months after the CLTX CAR T cell infusion. Tumour progression was seen only in the left temporal lobe which did not receive CLTX CAR T infusion. Like all patients in this dose level, patient 487 received a dose of 44 X 106 CLTX CAR T cells through a single intratumoral route of administration. LEVEL 3, 62 LYGON STREET CARLTON VIC 3053 AUSTRALIA

This finding, that tumour recurrence was prevented in the area where the CLTX CAR T cells were infused and tumour progression occurred in areas away from where the CLTX CAR T cells were infused, is important as it suggests that the dual routes of administration (intratumoral and intraventricular) of the CLTX CAR T cells in dose levels 2-4 may provide additional hope for patients. In the initial abstract presentation of patients treated at the 1st dose level, a disease control rate of 75% was shown as 3 out of the 4 patients treated achieved a best response of stable disease assessed by RANO criteria. Additional details provided within the final presentation demonstrated that the disease control observed was durable for approximately 5-8 weeks.

The final presentation of the CLTX CAR T CTIM-29 abstract also provided additional insight into the generally well tolerated adverse event profile of CLTX CAR T, showing that there were no CRS events, an adverse event often associated with CAR T cell therapy. Confirmation that the one grade 3 cerebral edema event was only possibly attributed to the CAR T cells was also presented. Cerebral edema is an adverse event commonly observed in patients with glioblastoma.

Chimeric’s CEO and Managing Director Jennifer Chow said: "Being able to see tumour control where the CLTX CAR T cells were administered in the brain and tumour progression where they were not administered is very promising – particularly at this low initial dose. That, in addition to the durability of the disease control for up to 8 weeks gives us great reason for optimism as we progress to more active dose levels with dual routes of administration."

In addition, the presentation of abstract EXTH-10 provided early confirmation of the role of MMP-2 expression in CLTX CAR T tumour recognition and killing. Data presented showed that MMP-2 expression levels increased with tumour grade and that CLTX CART T cells preferentially kill tumour target cells with higher MMP-2 expression, suggesting that CLTX CAR T may be effective even against the most aggressive cancers.

Within the presentation, early staining of a melanoma cell line was also presented confirming strong MMP-2 expression and providing early support for expanding the clinical development program for CLTX CAR T into additional solid tumours, including melanoma. LEVEL 3, 62 LYGON STREET CARLTON VIC 3053 AUSTRALIA

About the CLTX CAR T (CHM1101) Clinical Trial:
The CLTX CAR T phase 1 clinical trial is currently in progress at a single site in California with plans to expand to a multi-site trial in 2022. The design is a single arm, open label trial in patients with MMP2+ recurrent or progressive glioblastoma.

The primary endpoints of the trial are to assess the safety of CLTX CAR T cells, determine the maximum tolerated dose schedule and a recommended Phase 2 dosing plan. Secondary endpoints include bioactivity and efficacy measures.

The trial is designed with 4 dose levels ranging from 44 X 106 to 440 X 106 CLTX CAR T cells and studies both single and dual routes of administration of cells. Dose level 1 was completed with no dose limiting toxicities in April 2021.

Investor webinar
Chimeric Therapeutics CEO and Managing Director Jennifer Chow will hold an investor webinar today, Monday 22 November 2021, at 11:30am AEDT to elaborate on this announcement and take questions.

Click the link below to register: View Source

After registering, you will receive a confirmation email about how to join the webinar. A recording of the webinar will be available at the same link shortly after the conclusion of the session.